Non-Core Brands Downside Contribute to ANI Pharma's (ANIP) Revenue Miss; Roth Capital Reiterates Buy

Go back to Non-Core Brands Downside Contribute to ANI Pharma's (ANIP) Revenue Miss; Roth Capital Reiterates Buy

ANI Pharma (ANIP) Tops Q3 EPS by 17c

November 3, 2015 9:14 AM EST

ANI Pharma (NASDAQ: ANIP) reported Q3 EPS of $0.80, $0.17 better than the analyst estimate of $0.63. Revenue for the quarter came in at $20 million versus the consensus estimate of $21.37 million.

ANI Pharma sees Q4 2015 EPS of $0.60-$0.76, versus the consensus of $0.70. ANI Pharma sees Q4 2015... More

Trading Radar for 11/3: Groupon (GRPN), Mosaic (MOS), Kellogg (K), Herbalife (HLF), Zillow (Z) Report

November 2, 2015 2:23 PM EST

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Earnings:

1-800-FLOWERS.com (Nasdaq: FLWS) - consensus loss $0.26
ALLETE, Inc. (NYSE: ALE) - consensus EPS $1.00
AMAG Pharma (Nasdaq: AMAG) - consensus EPS $1.21
ANI Pharma (Nasdaq: ANIP) - consensus EPS $0.63
ARIAD Pharma0 (Nasdaq: ARIA) - consensus loss $0.23
Aircastle Limited (NYSE: AYR) - consensus EPS... More

ANI Pharma (ANIP) Announces U.S. Launch of Generic Vancocin Caps

November 2, 2015 8:22 AM EST

ANI Pharma (NASDAQ: ANIP) announced the launch of Vancomycin HCl 125mg and 250mg capsules indicated for treatment of C. difficile-associated diarrhea. The overall US market for Vancomycin HCl Capsules is approximately $113 million, per IMS Health.

Arthur S. Przybyl, President and Chief... More